Get all premium features to the best stock analysis tool

Tozorakimab met primary endpoint in both OBERON and TITANIA Phase III trials in patients with COPD

WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the Phase III OBERON and TITANIA trials in patients with chronic obstructive pulmonary disease (COPD) showed that tozorakimab reduced the annualized rate of moderate-to-severe COPD exacerbations compared with placebo, in the primary population of former smokers, and in the overall population, which included former and current smokers, and patients across all blood eosinophil* counts and all stages of lung function severity. Toz.

AstraZeneca and Joshua Jackson partner to encourage fans to Get Body Checked Against Cancer

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca and Joshua Jackson have teamed up as part of a national public health campaign designed to encourage fans to Get Body Checked Against Cancer and be proactive in speaking with their doctor. Joshua Jackson brings a unique cultural relevance to the initiative, resonating with a generation that grew up watching him on screen and is now entering a life stage where conversations about cancer risk and screenings become increasingly important. To help brin.

AstraZeneca awards $3.4 million for programs to improve access to healthcare for patients across the US

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca has proudly awarded $3.4 million to nonprofit organizations in the US through its Accelerate Change Together (ACT) on Health Equity initiative. This effort aims to support programming that prioritizes the social, cultural and linguistic needs of communities that have experienced barriers to care and opportunity. During its fifth year, AstraZeneca's ACT on Health Equity initiative will fund 47 nonprofit programs whose missions support the goal of ad.

AstraZeneca results: FY and Q4 2025

CAMBRIDGE, England--(BUSINESS WIRE)--AstraZeneca: Revenue and EPS summary   FY 2025 % Change Q4 2025 % Change   $m Actual CER1 $m Actual CER - Product Sales 55,573 9 9 14,538 9 7 - Alliance Revenue 3,067 39 38 959 34 33 Product Revenue2 58,640 10 10 15,497 10 8 Collaboration Revenue 99 (89) (89) 6 (99) (99) Total Revenue 58,739 9 8 15,503 4 2 Reported EPS ($) 6.60 45 43 1.50 55 47 Core3 EPS ($) 9.16 12 11 2.12 1 (2) Key performance elements for FY 2025 (Growth numbers at constant exchange rates.